Avidity Biosciences, Inc. - Common Stock (RNA)
70.09
+20.94 (42.59%)
NASDAQ · Last Trade: Oct 27th, 10:36 AM EDT
Detailed Quote
| Previous Close | 49.15 |
|---|---|
| Open | 70.31 |
| Bid | 70.08 |
| Ask | 70.09 |
| Day's Range | 70.00 - 70.39 |
| 52 Week Range | 21.51 - 56.00 |
| Volume | 27,802,553 |
| Market Cap | 3.82B |
| PE Ratio (TTM) | -19.63 |
| EPS (TTM) | -3.6 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,698,434 |
Chart
About Avidity Biosciences, Inc. - Common Stock (RNA)
Avidity Biosciences Inc is a biotechnology company focused on developing innovative therapies that leverage its proprietary AOC platform, which stands for antibody-oligonucleotide conjugates. This platform aims to deliver therapeutic oligonucleotides directly to specific cells using antibodies, thereby enhancing the precision and effectiveness of treatments for various diseases, including genetic disorders and cancer. The company's research is centered around improving the delivery and efficacy of RNA-based therapies, with the goal of transforming the treatment landscape for patients through targeted and personalized medicine. Read More
News & Press Releases
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · October 27, 2025
Via Benzinga · October 27, 2025
Via Benzinga · October 27, 2025
Via Benzinga · October 27, 2025
Dow Futures Rise As China Trade Tensions Ease: NVDA, MP, BA, RNA Among Stocks To Watchstocktwits.com
Via Stocktwits · October 27, 2025
Why Is Avidity Biosciences Stock Down 20% Pre-market Today?stocktwits.com
Via Stocktwits · September 11, 2025
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.
Via Benzinga · October 27, 2025
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.
Via Stocktwits · October 27, 2025
U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher.
Via Benzinga · October 27, 2025
Via Benzinga · October 27, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
By Halper Sadeh LLC · Via GlobeNewswire · October 26, 2025
Via Benzinga · October 22, 2025
Via Benzinga · September 23, 2025
Via Benzinga · September 15, 2025
Via Benzinga · September 12, 2025
Via Benzinga · September 11, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · September 11, 2025
Via Benzinga · September 11, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · September 11, 2025
Via Benzinga · September 11, 2025
Via Benzinga · September 11, 2025
Via Benzinga · September 10, 2025
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · September 10, 2025
Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year.
Via Benzinga · September 10, 2025
Via Benzinga · September 10, 2025